HTIT has recently submitted a marketing authorisation application in China for first oral insulin for type 2 diabetes
type 2 diabetes
It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR…
MKP10241 is a potent and orally administered small molecule, GPR119 agonist.
The FDC will be marketed under two brand names, Remo V and Remozen V, priced at Rs 14 per tab and Rs 28 per day cost of therapy
T2D market growth factors are increasing diagnosed prevalence of disease and the emergence of novel pipeline agents
The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11 trial
Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart…
In a breakthrough, scientists have discovered a key mechanism that triggers changes in the blood vessels, which can eventually…
Reportedly, the PTAB also found Sanofi’s proposed amended claims for the ‘486 and ‘844 patents unpatentable.
Zomelis is used in the treatment of type 2 diabetes and comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors